Post-Market Surveillance as part of the EU MDR and IVDR

by | Dec 13, 2019 | Classification, EU, EU MDR, FDA, Medical Devices, Quality Systems

The new European Medical Device Regulations and the In Vitro Diagnostic Devices regulation have a lot emphasis on the post-market activities that a manufacturer must undertake. With the clock ticking fast to meet the deadline for the transition period, which is May 2020 for EU MDR and May 2022 for the IVDR, coupled with the prevalent issues the industry is facing in interpreting the standard and without much guidance available from the European Commission, there is a lot of confusion in the industry as to how to implement the requirements.

As part of the post-market surveillance system, the regulation requires that the PMS system must:1

  • Be proportionate to the risk class and appropriate for the type of device
  • Be proactive and systematic
  • Integrate vigilance reporting requirements and allow co-operation on market surveillance
  • Connect with corrective action or preventive action processes
  • Allow updates to technical documentation, including the risk-benefit determination, labeling
  • and clinical evaluation/performance evaluation
  • Be part of the manufacturer’s QMS

The regulations require that a manufacturer must have a post-market surveillance plan in place. This plan should describe the implementation of the post-market surveillance system including the information to be collected, the method and the process to access the information. The plan must be approved by your notified body before you execute it since as per the new MDR and the IVDR, the NBs play a more active role in the pre and post-market activities of the company.1

Your post-market surveillance will tell the whole story about how well your plan was executed. The report should summarize the results of any data analysis done, as well as any CAPAs opened and the proposed action plan. More specific information such as conclusions that were drawn from the analysis and its use in risk-benefit determination, volume of sales and the estimate of the population using the device. PMS reports are applicable to class I medical devices and class A and B in vitro diagnostic medical devices.1

Preparing these reports can be confusing and EMMA International can help you in your transition efforts to the new regulations. Give us a call today at 248-987-4497 or email us at info@emmainternational.com.


1BSI- Post-market surveillance under the MDR and IVDR retrieved on 12/05/2019 from file:///C:/Users/Nikita%20Angane/Downloads/post_market_surveillance.pdf

 

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.
Is your product a medical device?

Is your product a medical device?

Many marketed products are classified as medical devices and you would not even know it. Medical devices range from latex gloves and tongue depressors to respirators and heart valves. To determine if the product is considered a medical device by the Food and Drug Administration (FDA) you will need to analyze if your product meets the definition of a medical device per the Food, Drug, and Cosmetic Act1.

Ready to learn more about working with us?

Pin It on Pinterest

Share This